BioSpace News Archive

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced the pricing of its previously announced underwritten public offering of 8,333,334 of its ordinary shares at a price to the public of $12.00 per ordinary share.

Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies

MONTREAL, Sept. 23, 2020 /PRNewswire/ - Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it will report its financial results and highlights for the third quarter ended July 31, 2020 on Tuesday September 29, 2020 after market close.

Evergreen Theragnostics, Inc., a radiopharmaceutical Contract Development and Manufacturing Organization, celebrated the groundbreaking for its new manufacturing facility in Springfield, New Jersey.

Combination trial, led by UCLA Medical Center and Principal Investigator Gary Shiller, MD, supported by mechanistic rationale and demonstrated synergy of combining venetoclax with targeted radiation from Actimab-A in preclinical studies

Veeva Vault CDMS and Bioforum selected to optimize clinical data management for RedHill’s global Phase 2/3 clinical trial evaluating opaganib in patients with severe COVID-19

Humanigen, Inc. announced a strategic collaboration with Thermo Fisher Scientific, a world leader in serving science, to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19, to support a potential Emergency Use Authorization.

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 23, 2020 / Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) (“Pascal” or the “Company”) today announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Four different laboratories have now experimentally verified the antiviral activity of a cannabinoid. In addition, several cannabinoids have been tested, and the optimal compoun

Aytu BioScience, Inc. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter and FY 2020 conference call, previously scheduled for Thursday, September 24 at 4:30pm ET.

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the pricing of an upsized public offering of 6,000,000 shares of its common shares at a price of $34.00 per share.